



Forward Thinking Healthcare

Fresenius is a **global healthcare group** offering high-quality products and services for dialysis, hospitals, and outpatient treatment. With over 200,000 employees in more than 100 countries around the globe, and annual sales exceeding €25 billion, Fresenius is one of the world's leading healthcare companies.

At Fresenius, **the patient always comes first**. For more than 100 years now we have been working to save lives and improve the quality of life of our patients. A clear focus on innovation and efficiency has helped us to **make high-quality healthcare accessible** to a steadily increasing number of people. Yet we never get complacent about our successes, and never stop looking for better solutions: this is how Fresenius is contributing to **medical progress** and better patient care.

Success in our businesses is the foundation for everything we do. Only an economically strong company can afford to make the continuing investments essential to providing high-quality yet affordable healthcare. This is how we are meeting our social responsibility and our commitment to patients, while ensuring that Fresenius remains successful over the long term.

We will continue to look ahead, finding new ways to help our patients even more and to help even more patients around the world. That is why Fresenius is **Forward Thinking Healthcare**.

FRESENIUS GROUP IN FIGURES (U.S. GAAP)

| € millions | 2015 | 2014 | 2013 |
|--------------------------------|--------------------|----------------|----------------|
| Sales and Earnings | | | |
| Sales | 27,626 | 23,231 | 20,331 |
| EBIT | 3,958 | 3,158 | 3,045 |
| EBIT margin | 14.3% | 13.6% | 15.0% |
| Net income | 1,423 | 1,086 | 1,051 |
| Operating cash flow | 3,327 | 2,585 | 2,320 |
| Balance sheet | | | |
| Total assets | 43,170 | 39,788 | 32,663 |
| Equity ratio | 42% | 39% | 41% |
| Debt ratio ¹ | 2.68 | 3.24 | 2.54 |
| Investments | 2,029 | 3,795 | 3,827 |
| Employees (December 31) | 222,305 | 216,275 | 178,337 |
| Share | | | |
| Number of shares | 545,727,950 | 541,532,600 | 539,084,487 |
| Market capitalization | 36,002 | 23,373 | 20,054 |
| Per share in €: | | | |
| Dividend | 0.552 ² | 0.44 | 0.42 |
| Earnings | 2.61 | 2.01 | 1.96 |

Some figures adjusted for special items

¹Net debt/EBITDA

²Subject to approval by the Annual General Meeting on May 13, 2016



SALES BY BUSINESS SEGMENT

| € millions | 2015 | 2014 | Change |
|------------------------|--------|--------|--------|
| Fresenius Medical Care | 15,086 | 11,917 | 27% |
| Fresenius Kabi | 5,950 | 5,146 | 16% |
| Fresenius Helios | 5,578 | 5,244 | 6% |
| Fresenius Vamed | 1,118 | 1,042 | 7% |

Fresenius Medical Care is the world's largest provider of **products and services** for individuals with **renal diseases** of which around 3 million patients worldwide regularly undergo dialysis treatment. Through its network of more than 3,000 dialysis clinics, Fresenius Medical Care provides dialysis treatments for around 300,000 patients around the globe. Fresenius Medical Care is also the leading provider of dialysis products such as dialysis machines or dialyzers. Along with the core business, the company focuses on expanding the range of additional medical services in the field of care coordination.

KEY FIGURES

| | 2015 US\$ millions | 2014 US\$ millions | Change |
|----------------------------------|-----------------------|-----------------------|--------|
| Sales | 16,738 | 15,832 | 6% |
| EBIT | 2,388 | 2,271 | 5% |
| Net income | 1,082 | 1,058 | 2% |
| Operating cash flow | 1,960 | 1,861 | 5% |
| Capital expenditure/acquisitions | 1,380 | 2,919 | -53% |
| R & D expenses | 140 | 122 | 15% |
| Employees (December 31) | 110,242 | 105,917 | 4% |

Some figures adjusted for special items

Net income = Net income attributable to the parent company of the respective business segment

Fresenius Kabi is a global healthcare company that specializes in medicines and technologies for **infusion, transfusion** and **clinical nutrition**. The company's products and services are used to help care for critically and chronically ill patients. Fresenius Kabi's product portfolio comprises a comprehensive range of I.V. generic drugs, infusion therapies and clinical nutrition products as well as the medical devices for administering these products. Within transfusion technologies, Fresenius Kabi offers products for collection and processing of blood components and for therapeutic treatment of patient blood by apheresis systems.

KEY FIGURES

| | 2015 € millions | 2014 € millions | Change |
|----------------------------------|--------------------|--------------------|--------|
| Sales | 5,950 | 5,146 | 16% |
| EBIT | 1,189 | 873 | 36% |
| Net income | 669 | 468 | 43% |
| Operating cash flow | 913 | 641 | 42% |
| Capital expenditure/acquisitions | 389 | 479 | -19% |
| R & D expenses | 336 | 276 | 22% |
| Employees (December 31) | 33,195 | 32,899 | 1% |

Fresenius Helios is the **largest German private hospital operator**. The HELIOS Group operates more than 100 proprietary clinics with a total of more than 30,000 beds, including seven maximum care clinics in Berlin-Buch, Duisburg, Erfurt, Krefeld, Schwerin, Wiesbaden and Wuppertal. A majority of Fresenius Helios clinics are acute care facilities, but the company also owns post-acute care clinics. The company's goal is to provide high-quality, state-of-the-art treatment and care in all areas and at all care levels in its hospitals. Fresenius Helios has around 70,000 employees and treats more than 4 million patients – including more than 1 million inpatients – annually.

KEY FIGURES


| | 2015 € millions | 2014 € millions | Change |
|----------------------------------|--------------------|--------------------|--------|
| Sales | 5,578 | 5,244 | 6% |
| EBIT | 640 | 553 | 16% |
| Net income | 483 | 400 | 21% |
| Operating cash flow | 618 | 558 | 11% |
| Capital expenditure/acquisitions | 376 | 1,090 | -66% |
| Employees (December 31) | 69,728 | 68,852 | 1% |

Fresenius Vamed is a global provider of services in **planning, constructing and managing health care facilities**. With its approach of “everything from one source,” the company offers hospitals a complete value chain to achieve and maintain efficiency at every stage: from project development, planning and turnkey construction to facility and total operational management. Headquartered in Vienna, Austria, Fresenius Vamed boasts a track record of more than 700 completed health care projects in more than 70 countries since its founding in 1982.

KEY FIGURES


| | 2015 € millions | 2014 € millions | Change |
|----------------------------------|--------------------|--------------------|--------|
| Sales | 1,118 | 1,042 | 7% |
| EBIT | 64 | 59 | 8% |
| Net income | 44 | 41 | 7% |
| Operating cash flow | 53 | -9 | - |
| Capital expenditure/acquisitions | 15 | 22 | -32% |
| R & D expenses | 904 | 840 | 8% |
| Employees (December 31) | 8,262 | 7,746 | 7% |

SALES BY REGION



2015: €27.6 billion

EMPLOYEES BY REGION



2015: 222,305



Corporate Headquarters

Else-Kröner-Strasse 1
Bad Homburg v. d. H.
Germany

Postal address

Fresenius SE & Co. KGaA
61346 Bad Homburg v. d. H.
Germany

www.facebook.com/fresenius.group
www.twitter.com/fresenius
www.youtube.com/freseniustv

www.fresenius.com

Contact for journalists

Corporate Communications
T +49 6172 608-2302
F +49 6172 608-2294
pr-fre@fresenius.com

Contact for shareholders

Investor Relations
T +49 6172 608-2487
F +49 6172 608-2488
ir-fre@fresenius.com